摘要
目的观察紫杉醇联合奈达铂(NDP)方案治疗放疗后进展或复发的中晚期食管癌的临床疗效及毒副反应。方法非手术、放疗后进展或复发,Ⅱ～Ⅳ期食管癌患者,紫杉醇135 mg·m-2静脉点滴;奈达铂90 mg·m-2静脉点滴,28 d为1个周期,2个周期结束后评价疗效。疗程内6个治疗周期或出现不可耐受毒性为止。结果治疗周期中位值为5,可评价51例,完全缓解(CR)3例,部分缓解(PR)21例,有效(CR+PR)率47.1%(24/51),中位无进展生存期(PFS)20个月。主要副反应发生率:恶心呕吐7.8%(4/51),白细胞减少13.7%(7/51),血小板计数减少9.8%(5/51)。结论紫杉醇联合奈达铂治疗进展或复发的中晚期食管癌近期疗效确切,安全性较好。
Aim To evaluate the efficacy and toxicity of paclitaxel combined with nedaplatin in advanced or recurrent esophageal cancer after radiotherapy.Methods Fifty-one esophageal advanced or recurrent patients whith pathologic stage in Ⅱ~Ⅳ were treated with paclitaxel 135 mg·m-2 drips in the first day and nedaplatin 90 mg·m-2 in the second day.The regimen was repeated every 28 days and we evaluated it after continuous 2 treatment cycles,and we did not end it until the occurrence of intolerable toxicity within 6 treatment cycles.Results The treatment cycle median value was 5 for the 51 patients.The total effective rate was 47.1 %,including 3 cases of CR and 21 cases of PR and 20 months of PFS.The incidence of major side effects included nausea and vomiting 7.8%（4/51）,leucopenia 13.7%（7/51）and decrease of platelet count by 9.8%（5/51）in patients.Conclusion Paclitaxel combined with nedaplatin in treating advanced esophageal carcinoma is effective and well tolerated.
出处
《安徽医药》
CAS
2011年第4期492-493,共2页
Anhui Medical and Pharmaceutical Journal
关键词
紫杉醇
奈达铂
化学治疗
中晚期食管癌
paclitaxel
nedaplatin
chemotherapy
advanced esophageal cancer
